The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The prognostic value of patient-reported fatigue in aggressive B-cell lymphoma treated with CAR-T
In this video, Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, briefly discusses the prognostic value of patient-reported fatigue in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy, highlighting that assessing fatigue pre-infusion is crucial, as it may help predict survival outcomes. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
One of the key aspects of these patients is to better understand from the very beginning who are those patients who can actually have adverse outcomes during therapy, who are the most vulnerable group of patients. So what we have seen is to analyze the prognostic value of pre-infusion characteristics for survival outcomes. And we have seen that patient-reported fatigue provides independent prognostic information beyond what we might have expected to be prognostic in this population...
One of the key aspects of these patients is to better understand from the very beginning who are those patients who can actually have adverse outcomes during therapy, who are the most vulnerable group of patients. So what we have seen is to analyze the prognostic value of pre-infusion characteristics for survival outcomes. And we have seen that patient-reported fatigue provides independent prognostic information beyond what we might have expected to be prognostic in this population. So we’re controlling the analysis for a number of sociodemographic and clinical characteristics of these patients at baseline, that is pre-infusion, but actually fatigue stands out as a very important independent prognostic information for survival. So the key message is that physicians should pay special attention to measuring fatigue pre-infusion, because this might provide very important prognostic indications. So we should assess more systematically fatigue pre-infusion in this population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
